These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 22450347)

  • 1. Plasma von Willebrand factor antigen levels are elevated in the classic phenotypes of polycystic ovary syndrome.
    Koiou E; Tziomalos K; Katsikis I; Dinas K; Tsourdi EA; Kandaraki EA; Delkos D; Papadakis E; Panidis D
    Hormones (Athens); 2012; 11(1):77-85. PubMed ID: 22450347
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Insulin resistance and endocrine characteristics of the different phenotypes of polycystic ovary syndrome: a prospective study.
    Panidis D; Tziomalos K; Misichronis G; Papadakis E; Betsas G; Katsikis I; Macut D
    Hum Reprod; 2012 Feb; 27(2):541-9. PubMed ID: 22144419
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-Mullerian hormone levels reflect severity of PCOS but are negatively influenced by obesity: relationship with increased luteinizing hormone levels.
    Piouka A; Farmakiotis D; Katsikis I; Macut D; Gerou S; Panidis D
    Am J Physiol Endocrinol Metab; 2009 Feb; 296(2):E238-43. PubMed ID: 18957615
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma plasminogen activator inhibitor-1 levels in the different phenotypes of the polycystic ovary syndrome.
    Koiou E; Tziomalos K; Dinas K; Katsikis I; Kandaraki EA; Tsourdi E; Mavridis S; Panidis D
    Endocr J; 2012; 59(1):21-9. PubMed ID: 21996594
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Role of Anti-Müllerian Hormone in the Characterization of the Different Polycystic Ovary Syndrome Phenotypes.
    Romualdi D; Di Florio C; Tagliaferri V; De Cicco S; Gagliano D; Immediata V; Lanzone A; Guido M
    Reprod Sci; 2016 May; 23(5):655-61. PubMed ID: 26718304
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The phenotypes of polycystic ovary syndrome defined by the 1990 diagnostic criteria are associated with higher serum vaspin levels than the phenotypes introduced by the 2003 criteria.
    Koiou E; Dinas K; Tziomalos K; Toulis K; Kandaraki EA; Kalaitzakis E; Katsikis I; Panidis D
    Obes Facts; 2011; 4(2):145-50. PubMed ID: 21577021
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selected markers of endothelial dysfunction in women with polycystic ovary syndrome.
    Foltyn W; Strzelczyk J; Marek B; Kajdaniuk D; Siemińska L; Zemczak A; Blicharz-Dorniak J; Kos-Kudła B
    Endokrynol Pol; 2011; 62(3):243-8. PubMed ID: 21717407
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Polycystic ovary syndrome: cardiovascular risk factors according to specific phenotypes.
    Aziz M; Sidelmann JJ; Faber J; Wissing ML; Naver KV; Mikkelsen AL; Nilas L; Skouby SO
    Acta Obstet Gynecol Scand; 2015 Oct; 94(10):1082-9. PubMed ID: 26123797
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Body Mass Index below Obesity Threshold Implies Similar Cardiovascular Risk among Various Polycystic Ovary Syndrome Phenotypes.
    Bagir GS; Bakiner OS; Bozkirli E; Cavlak G; Serinsoz H; Ertorer ME
    Med Princ Pract; 2016; 25(1):61-6. PubMed ID: 26335185
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Uterine volume and endometrial thickness in the early follicular phase in patients with polycystic ovary syndrome.
    Panidis D; Tziomalos K; Papadakis E; Vosnakis C; Betsas G; Tsourdi E; Katsikis I
    Endocr Pract; 2014 Jun; 20(6):540-7. PubMed ID: 24325993
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anthropometric, clinical and laboratory comparison of four phenotypes of polycystic ovary syndrome based on Rotterdam criteria.
    Yilmaz M; Isaoglu U; Delibas IB; Kadanali S
    J Obstet Gynaecol Res; 2011 Aug; 37(8):1020-6. PubMed ID: 21481088
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased circulating soluble P-selectin in polycystic ovary syndrome.
    Yildiz BO; Bozdag G; Harmanci A; Otegen U; Boynukalin K; Vural Z; Kirazli S; Haznedaroglu IC; Yarali H
    Fertil Steril; 2010 May; 93(7):2311-5. PubMed ID: 19261277
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Associations of menstrual cycle irregularities with age, obesity and phenotype in patients with polycystic ovary syndrome.
    Panidis D; Tziomalos K; Papadakis E; Chatzis P; Kandaraki EA; Tsourdi EA; Macut D; Bjekic-Macut J; Marthopoulos A; Katsikis I
    Hormones (Athens); 2015; 14(3):431-7. PubMed ID: 26188231
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-mullerian hormone is associated with advanced glycosylated end products in lean women with polycystic ovary syndrome.
    Diamanti-Kandarakis E; Piouka A; Livadas S; Piperi C; Katsikis I; Papavassiliou AG; Panidis D
    Eur J Endocrinol; 2009 May; 160(5):847-53. PubMed ID: 19208775
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vascular risk in young women with polycystic ovary and polycystic ovary syndrome.
    Battaglia C; Mancini F; Cianciosi A; Busacchi P; Facchinetti F; Marchesini GR; Marzocchi R; de Aloysio D
    Obstet Gynecol; 2008 Feb; 111(2 Pt 1):385-95. PubMed ID: 18238977
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oxidative stress but not endothelial dysfunction exists in non-obese, young group of patients with polycystic ovary syndrome.
    Kuşçu NK; Var A
    Acta Obstet Gynecol Scand; 2009; 88(5):612-7. PubMed ID: 19308750
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metabolic aspects of different phenotypes of polycystic ovary syndrome: Iranian PCOS Prevalence Study.
    Hosseinpanah F; Barzin M; Keihani S; Ramezani Tehrani F; Azizi F
    Clin Endocrinol (Oxf); 2014 Jul; 81(1):93-9. PubMed ID: 24428207
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical and metabolic characteristics of Turkish adolescents with polycystic ovary syndrome.
    Ates S; Aydın S; Ozcan P; Soyman Z; Gokmen Karasu AF; Sevket O
    J Obstet Gynaecol; 2018 Feb; 38(2):236-240. PubMed ID: 28920502
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oligoanovulation with polycystic ovaries but not overt hyperandrogenism.
    Dewailly D; Catteau-Jonard S; Reyss AC; Leroy M; Pigny P
    J Clin Endocrinol Metab; 2006 Oct; 91(10):3922-7. PubMed ID: 16849400
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is hyperandrogenemia protective for fibrocystic breast disease in PCOS?
    Ozkaya E; Cakir E; Cinar M; Kara F; Baser E; Cakir C; Kucukozkan T
    Gynecol Endocrinol; 2012 Jun; 28(6):468-71. PubMed ID: 22103710
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.